Translating Metabolic Responses to Mechanical Insult Into Early Interventions to Prevent PTOA
Key facts
- Who runs it
- J L Marsh
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 5 people enrolled
- Started
- 20 Jul 2022
- Ended
- 1 May 2025
- Type of study
- Interventional, 5 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- amobarbital/Gel-One (one dose)
- Placebo (single dose)
- amobarbital/Gel-One (two doses)
- Placebo (two doses)
- Record updated
- 6 July 2026
- Why it stopped
- Phase I portion was completed. Phase II will now be completed at a different institution.
Who can take part
- Age
- 18 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Age 18-60 years
- Acute closed or type 1 open ankle fractures (classified as OTA/AO 43 B 1-3 and 43 C 1- 3 or classified as 42 B and C fractures with 25% talar displacement and one of the following; syndesmosis injury or medial malleolar fracture at or above the shoulder) (Marsh et al., 2007)) without operative ipsilateral extremity trauma
- Posterior malleolar and supination adduction rotational fractures that have an articular fracture line across the articular surface of the distal tibia. Posterior malleolar fractures should affect 25% of the articular surface or greater
- Fractures must have initial treatment within 72 hours of injury including initial injection of amobarbital or placebo
Who cannot take part
- Previous injuries to the ankle
- Diabetes
- Allergy to poultry products or cinnamon
- Pre-existing immunologic or hematologic diseases
- Pre-existing dysfunction of the kidneys, liver, blood, immune system, endocrine system (excluding diabetes)
- Serum creatinine >/= 1.4 mg/dl; BUN > 30 mg/dl; ALT >/= 60 IU/L in males and >/= 50 IU/L in females; AST >/= 45 IU/L in males and > 40 IU/L in females; bilirubin > 1.3 mg/dL; platelets </= 50,000/ul; glucose > 200 mg/dL
- Pregnant or nursing mothers and individuals with child-bearing potential that are not using birth control methods with >99% efficacy
- High grade open wounds
- Pre-existing ankle arthritis
- Ipsilateral fractures
- Associated injuries that preclude standard rehabilitation
Where in United States
- University of IowaIowa City, United States
About the trial
What the trial wants to find out
This is a small-scale proof-of concept clinical trial of amobarbital as a treatment to prevent post-traumatic osteoarthritis in fractured ankle joints. The study is a double blind, prospective, randomized, placebo-controlled, stepwise trial. Amobarbital will be delivered to ankle joints in solution with hyaluronic acid (HA) as a vehicle. Amobarbital/HA injections (active dose) will be compared to HA alone (placebo dose). Our primary goal is to confirm safety, but we will also assess whether treatment improves chondrocyte viability and decreases synovial inflammation. The intervention that will be utilized has proven to be effective using vitro and in vivo models. The study team will assess safety and begin to evaluate efficacy of amobarbital/Gel-One in patients having sustained tibial pilon fractures. The study team will use advanced imaging-based methods we have developed to characterize how joints subjected to varying levels of fracture severity and residual elevated contact stress respond in treated and control groups.
The 5 groups in the trial
- Phase I single amobarbital/Gel-One doseTreatment being tested
Phase I: An open label study of 3 patients will be done. If no dose limiting toxic (DLT) side effects occur, then an additional 3 patients will be done. If no DLT events occur, the study will proceed to Phase II.
Treatment: amobarbital/Gel-One (one dose)
- Phase IIa Part 1 amobarbital/Gel-One doseExisting treatment, for comparison
20 subjects will be randomized to amobarbital/Gel-One single dose.
Treatment: amobarbital/Gel-One (one dose)
- Phase IIa Part 1 PlaceboPlacebo, for comparison
10 subjects will be randomized to amobarbital/Gel-One single dose.
Treatment: Placebo (single dose)
- Phase IIa Part 2 amobarbital/Gel-One doseExisting treatment, for comparison
20 subjects will be randomized to one dose of amobarbital/Gel-One during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Treatment: amobarbital/Gel-One (two doses)
- Phase IIa Part 2 placeboPlacebo, for comparison
20 subjects will be randomized to one dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Treatment: Placebo (two doses)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 6 July 2026